Inactive Instrument

Analyst Reco. Pfizer Inc. London S.E.

Equities

Tiny Chain Bridge is top banker to Trump, Republican campaigns	07-01	RE
DA Davidson Raises Price Target on Pfizer to $35 From $30, Maintains Buy/Add Rating	05-20	MT
Arbutus Biopharma Urged to Stop Share Issuances, Explore Alternatives for Hepatitis B Program	05-17	MT
Redburn Atlantic Adjusts Price Target on Pfizer to $27 From $26, Keeps Neutral Rating	05-13	MT
PFIZER INC : Buy rating from DZ Bank	05-02	ZD
Morgan Stanley Adjusts Price Target on Pfizer to $29 From $28	05-02	MT
Leerink Adjusts Price Target on Pfizer to $29 From $27	05-02	MT
BMO Capital Adjusts Pfizer's Price Target to $36 From $33, Keeps Outperform Rating	05-02	MT
Morgan Stanley Lifts Price Target on Pfizer to $29 From $28, Keeps Equalweight Rating	05-02	MT
PFIZER INC : Jefferies gives a Buy rating	05-01	ZD
PFIZER INC : UBS remains Neutral	05-01	ZD
PFIZER INC : JP Morgan remains Neutral	05-01	ZD
Connect Biopharma Terminates Agreement on Antiallergic Candidate With Pfizer	04-17	MT
Novavax Shareholder Shah Capital Pushes to Add 2 Nominees to Company's Board	04-15	MT
PFIZER INC : JP Morgan remains Neutral	04-12	ZD
Skanska Trims Scope of Work for Biomanufacturing Facility Project in US	04-12	MT
PFIZER INC : Berenberg remains Neutral	04-10	ZD
Argus Downgrades Pfizer to Hold From Buy	03-22	MT
PFIZER INC : JP Morgan sticks Neutral	03-07	ZD
PFIZER INC : JP Morgan sticks Neutral	03-01	ZD

No results for this search

Pfizer, Inc: A cycle for nothing?

December 14, 2023 at 10:58 am

Albert Bourla, Pfizer CEO (full interview): mRNA, acquisitions, weight-loss drugs